Details of Drug-Drug Interaction
| Drug General Information (ID: DDIRLEXUMJ) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Norfloxacin | Drug Info | Sitagliptin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antibiotics | Antidiabetic Agents | |||||||
| Structure | |||||||||
| Mechanism of Norfloxacin-Sitagliptin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Norfloxacin | Sitagliptin | |||||||
| Mechanism 1 | Hypoglycemic effects | Antidiabetic agent | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypoglycemia | ||||||||
| Factor Description | Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating. | ||||||||
| Mechanism Description |
|
||||||||
| Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Norfloxacin | Sitagliptin | |||||||
| Mechanism 2 | Hyperglycemia | Antidiabetic agent | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Mechanism 3 | Hyperglycemic effects | Antidiabetic agent | |||||||
| Key Mechanism Factor 3 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Patients should be apprised of the increased risk of dysglycemia and be particularly alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. alternative antibiotics may need to be considered. | ||||||||